View Clinical trials for Mivebresib Get Mivebresib Patent Info for Free

NCI: An inhibitor of one or more as of yet undisclosed bromodomain (BRD)-containing protein(s), with potential antineoplastic activity. Upon administration, the bromodomain inhibitor ABBV-075 binds to the acetyl-lysine binding site in the BRD of certain BRD-containing protein(s), thereby preventing the interaction between those proteins and acetylated histones. This disrupts chromatin remodeling, prevents the expression of certain growth-promoting genes, and leads to an inhibition of cell growth in susceptible tumors.

Inn NameMivebresib
Lab CodesABBV-075
Chemical NameN-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]ethanesulfonamide
Chemical StructureMivebresib.png
Molecular FormulaC22H19F2N3O4S
Cas Registry Number1445993-26-9
New Molecular EntityYes
Mechanism Of ActionBromodomain and extraterminal domain protein inhibitor
Who Atc CodesL01 (Antineoplastic Agents)
Ephmra CodesL1 (Antineoplastics)
IndicationAdvanced Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia, Multiple Myeloma

Free counters!